Tandem Diabetes Bullish Call Signals Long-Term Growth Confidence - Tandem Diabetes Care (NASDAQ:TNDM)
Published on March 17, 2026.
Tandem Diabetes Care Inc. (NASDAQ:TNDM) stock has risen following an analyst upgrade, indicating a long-term growth opportunity. Analyst Matt O'Brien upgraded from Neutral to Overweight, citing the company's shift to the pharmacy channel, international growth opportunities, and upcoming product catalysts. O'Neill estimates approximately $15 million in incremental pharmacy-related revenue upside in 2026, followed by an additional $33 million the next year. The analyst also raised the price forecast from $21 to $33. However, concerns were raised about Tandem's guidance for U.S. pump shipment growth, which is projected to increase 10% this year, marking a significant acceleration compared to prior years.
Related Articles
Micron shares slip as hefty spending plans eclipse strong AI-fueled earnings
Micron shares fell as heavy capex plans outweighed strong earnings from a surge in demand for high-end memory chips.
JCPS school psychologists defend positions in face of budget cuts
Jefferson County Public Schools are considering 13 contract days for school psychologists to cut costs and prevent service delays, despite concerns over staff shortages and service cuts.
How some couples could get a six-figure Social Security income in 2026
Despite the average retired worker receiving $2,076 per month from Social Security, some married couples can earn significantly more, potentially earning more than $10,000 per month.